Abstract:The neutrophil -to-lymphocyte ratio (NLR) is useful for predicting the effectiveness of treatment with immune checkpoint inhibitors (ICIs) and immune-related adverse events (irAEs). Because a growing body of evidence has recently shown that the number of lymphocytes that comprise NLR fluctuates according to nutritional status, this study examined whether the usefulness of NLR varies in ICI treatment due to changes in nutritional status. A retrospective analysis was performed on 1234 patients who received ICI treatment for malignant tumors at our hospital. Progression-free survival (PFS) was significantly prolonged in patients with NLR < 4. Multivariate analysis revealed that the factors associated with the occurrence of irAE were NLR < 4 and the use of ipilimumab. However, when limited to cases with serum albumin levels <3.8 g/dL, lymphocyte counts significantly decreased, and the associations between NLR and PFS and between NLR and irAE occurrence disappeared. In contrast, when limited to the cases with serum albumin levels ≥3.8 g/dL, the associations remained, with significantly prolonged PFS and significantly increased irAE occurrence at NLR < 4. NLR may be a good predictive tool for PFS and irAE occurrence during ICI treatment when a good nutritional status is maintained.

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve This paper aims to explore the impact of nutritional status on the neutrophil-to-lymphocyte ratio (NLR) as a predictor of the efficacy and adverse events of immune checkpoint inhibitors (ICIs). Specifically, the researchers want to understand whether NLR can still effectively predict the therapeutic efficacy of ICIs and the occurrence of immune-related adverse events (irAEs) under different nutritional statuses. ### Background and Research Motivation 1. **Application of Immune Checkpoint Inhibitors (ICIs)**: - ICIs have become the standard treatment for various malignancies. - ICIs enhance therapeutic efficacy by blocking specific molecules to activate the body's immune response against tumors. - However, ICIs can also lead to severe immune-related adverse events (irAEs). 2. **Role of NLR**: - NLR is widely regarded as a useful indicator for predicting the therapeutic efficacy of ICIs and the occurrence of irAEs. - NLR is primarily composed of the ratio of neutrophils to lymphocytes, and the number and function of lymphocytes can be affected by nutritional status. 3. **Impact of Nutritional Status**: - Many cancer patients are often in a state of malnutrition due to increased inflammatory cytokines, metabolic changes, and anorexia. - Malnutrition may affect the number and function of lymphocytes, thereby impacting the predictive ability of NLR. ### Research Methods 1. **Patient Selection**: - This study is a single-center retrospective observational study that included 1234 patients who received ICIs treatment at the hospital from January 2016 to December 2022. 2. **Data Collection**: - Baseline characteristics, serum albumin levels, lymphocyte and neutrophil counts, and other data were collected. - The Kaplan-Meier method was used to assess progression-free survival (PFS) and overall survival (OS), and Cox proportional hazards models and multivariable logistic regression analyses were used to identify factors associated with PFS and the occurrence of irAEs. ### Main Findings 1. **Relationship between NLR and PFS**: - When NLR < 4, patients' PFS was significantly prolonged. - However, when serum albumin levels were < 3.8 g/dL, the association between NLR and PFS disappeared; whereas, when serum albumin levels were ≥ 3.8 g/dL, patients with NLR < 4 had significantly prolonged PFS. 2. **Relationship between NLR and irAEs**: - NLR < 4 and the use of ipilimumab were independent predictors of the occurrence of irAEs. - When serum albumin levels were < 3.8 g/dL, the association between NLR and the occurrence of irAEs disappeared; whereas, when serum albumin levels were ≥ 3.8 g/dL, patients with NLR < 4 had a significantly increased incidence of irAEs. 3. **Impact of Nutritional Status**: - Serum albumin levels were positively correlated with lymphocyte counts, and low serum albumin levels were associated with low lymphocyte counts, leading to an increase in NLR. - Under malnutrition, NLR could no longer accurately predict the occurrence of irAEs and the therapeutic efficacy of ICIs. ### Conclusion In ICIs treatment, NLR has been considered a useful predictive tool for the occurrence of irAEs and therapeutic efficacy. However, if the patient's nutritional status is poor, the predictive ability of NLR may be reduced. Therefore, NLR may only have predictive value when serum albumin levels are high. This finding emphasizes the importance of maintaining good nutritional status during ICIs treatment.

Impact of Nutritional Status on Neutrophil-to-Lymphocyte Ratio as a Predictor of Efficacy and Adverse Events of Immune Check-Point Inhibitors

Neutrophil-lymphocyte Ratio As a Prognostic Factor for Stereotactic Body Radiotherapy Treatment of Metastatic Liver Tumors.

Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Neutrophil–lymphocyte Ratio and Platelet–lymphocyte Ratio As Potential Predictive Markers of Treatment Response in Cancer Patients Treated with Immune Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

Neutrophil–to–lymphocyte Ratio and Use of Antibiotics Associated with Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors

Neutrophil-to-lymphocyte ratio as a predictive biomarker for hyperprogressive disease mediated by immune checkpoint inhibitors: a systematic review and meta-analysis

Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events

The Prognostic Impact of Neutrophil to Lymphocyte Ratio in Patients with Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors.

The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis

Change in Neutrophial-to-lymphocyte Ratio (NLR) in Response to Immune Checkpoint Inhibitor for Advanced Gastric Cancer.

Association between the Prognostic Nutritional Index and the Occurrence of Immune-Related Adverse Events

Predictability of Neutrophile to Lymphocyte Ratio and Platelet to Lymphocyte Ratio on the Effectiveness of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer patients: A Meta-Analysis

Effect of neutrophil to lymphocyte ratio (NLR) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in real-world setting.

Utility of neutrophil-to-lymphocyte ratio as an indicator of tumor immune status in non-small cell lung cancer

Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio predicts post-stereotactic radiosurgery survival of patients with brain metastases concurrently treated with immune checkpoint inhibitors

Neutrophil to lymphocyte ratio may predict efficacy of anti-PD-1 inhibitors in advanced EGFR-mutant non-small cell lung cancer: retrospective cohort study

Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment

Neutrophil-lymphocyte ratio as a prognostic marker in a resource constraint setting for metastatic malignancies treated with immune checkpoint inhibitors

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

Neutrophil‐to‐lymphocyte ratio associates with nutritional parameters, intratumoral immune profiles, and clinical outcomes of pembrolizumab in head and neck squamous cell carcinoma